CD274 and Miyoshi myopathy: This suggests that novel immune priming strategies, such as oncolytic viral therapy, that stimulate upregulation of PD-L1 on malignant cells could render agents that target the PD-L1/PD-1 axis significantly more effective for cancer patients with low PD-L1 expression, including patients with MM.